Smith & Nephew (LON:SN) Reaches New 12-Month High – Still a Buy?

Smith & Nephew plc (LON:SN)’s stock price hit a new 52-week high during mid-day trading on Friday . The stock traded as high as GBX 1,293 and last traded at GBX 1,267, with a volume of 2148668 shares. The stock had previously closed at GBX 1,293.50.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on SN shares. Panmure Gordon reissued a “hold” rating and set a GBX 1,200 price target on shares of Smith & Nephew in a research report on Tuesday, December 9th. Citigroup boosted their price objective on shares of Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the stock a “buy” rating in a research note on Friday, October 31st. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Smith & Nephew in a research report on Friday, November 7th. Royal Bank Of Canada downgraded shares of Smith & Nephew to a “sector perform” rating and reduced their target price for the stock from GBX 1,700 to GBX 1,350 in a report on Wednesday, December 17th. Finally, Berenberg Bank reiterated a “hold” rating and set a GBX 1,300 price objective on shares of Smith & Nephew in a research note on Friday, January 23rd. Two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of GBX 1,381.33.

Smith & Nephew Stock Down 2.0%

The company’s 50-day moving average is GBX 1,234.95 and its 200 day moving average is GBX 1,292.61. The stock has a market capitalization of £13.89 billion, a PE ratio of 45.62, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62. The company has a current ratio of 2.51, a quick ratio of 0.84 and a debt-to-equity ratio of 70.22.

Insider Buying and Selling at Smith & Nephew

In related news, insider Deepak Nath sold 1,240 shares of Smith & Nephew stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of GBX 1,257, for a total transaction of £15,586.80. 0.19% of the stock is owned by company insiders.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.